Neumarker

Dr. Qiang Li, Chief Technology Officer of Neumarker Inc., presented a talk titled “An EEG-Based, Machine Learning Biomarker to Identify Responsive vs. Non-responsive Subjects in an MDD Clinical Trial: Initial Validation Data from the EMBARC Study Database” at the 2024 Annual Meeting of the American Society of Clinical Psychopharmacology (ASCP) in Miami. The presentation took place on Thursday, May 30, 2024.

Dr. Li’s presentation provided a comprehensive analysis of Neumarker’s advanced EEG-based machine learning technology, focusing on the identification of treatment responders, non-responders, and super placebo responders in clinical trials. The research offered significant potential for enhancing precision treatment strategies in clinical practice for patients diagnosed with Major Depressive Disorder (MDD) and Treatment-Resistant Depression (TRD).

Neumarker’s proprietary technology, which integrated baseline EEG measurements with sophisticated machine learning algorithms, represented a major advancement in clinical trial methodology. By enabling precise patient stratification, this biomarker technology aimed to enhance the predictive accuracy of treatment outcomes, thereby increasing the efficacy of clinical trials. The application of this tool in clinical settings could also facilitate the personalization of therapeutic strategies, ultimately improving patient outcomes for those affected by MDD and other psychiatric and neurological conditions.

About Neumarker

Neumarker is a leader in the innovation of CNS disorder treatments, specializing in brain biomarker discovery powered by artificial intelligence. The company’s mission is to accelerate drug development for CNS disorders by reducing heterogeneity among trial subjects and equipping clinicians with tools to deliver personalized, precision-based care. Neumarker collaborates closely with industry leaders and research institutions to advance precision neuro-medicine. For more information, visit http://www.neumarker.ai.